News

Imaging Endpoints Featured Speaker at 2nd Annual Immuno-Oncology 360°

Immuno-Oncology 360°

Imaging Endpoints CMO and Founder, Ronald Korn, MD., PhD. presents “Imaging the Immune System in Solid Tumors.”This talk will cover the spectrum of immunotherapy from an imaging perspective along with current trends including novel imaging methodologies and enhanced techniques beyond conventional imaging. The Immuno-Oncology 360° eventdelves into key areas of business, clinical and scientific advancements including the Business Aspects for IO, Differences of Modalities in Immunotherapy, Methodological Advances – Investigating Immunotherapies in the Clinic, Immunotherapy Practice Altering Clinical Advances, Hematologic Malignancies, Emerging Biomarkers and Randomized Phase II Combination Therapy Trials.  Visit us and learn how we can provide imaging expertise to help develop your product in translational and Phase I studies and provide core lab services for Phase I, II, III and IV. For more information, email us at info@imagingendpoints.com or call us at 480.314.3070.

February 2, 2016 – February 3, 2016

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas

Background: In the phase III MPACT trial, nab-paclitaxel plus gemcitabine (nab-P + Gem) demonstrated superior efficacy versus Gem alone for patients with metastatic pancreatic cancer. We sought to examine the feasibility of positron emission tomography (PET) and to compare metabolic…   Read More

Radiogenomic Analysis Demonstrates Associations between 18F-Fluoro-2-Deoxyglucose PET, Prognosis, and Epithelial-Mesenchymal Transition in Non–Small Cell Lung Cancer1

Purpose: To investigate whether non–small cell lung cancer (NSCLC) tumors that express high normalized maximum standardized uptake value (SUVmax) are associated with a more epithelial-mesenchymal transition (EMT)–like phenotype. Materials and Methods: In this institutional review board–approved study, a public NSCLC…   Read More

Dr. Korn published on PubMed: The Radiogenomic Risk Score: Construction of a Prognostic Quantitative, Noninvasive Image-based Molecular Assay for Renal Cell Carcinoma.

Dr. Ron Korn involved in study published to PubMed.
Abstract
PURPOSE:
To evaluate the feasibility of constructing radiogenomic-based surrogates of molecular assays (SOMAs) in patients with clear-cell renal cell carcinoma (CCRCC) by using data extracted from a single computed tomographic (CT) image.